Your session is about to expire
What is Diatrizoate Meglumine
DiatrizoateThe Generic name of this drug
Treatment SummaryDiatrizoate is a type of x-ray dye used to create a clearer image during diagnostic imaging tests. It can be used to study the gastrointestinal system, perform angiography, and diagnose urinary problems.
Renografin-60is the brand name
Diatrizoate Meglumine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Renografin-60
Diatrizoate
1956
23
Approved as Treatment by the FDA
Diatrizoate, also known as Renografin-60, is approved by the FDA for 12 uses which include Arteriography and Gastrointestinal and abdominal imaging procedures .Arteriography
Gastrointestinal and abdominal imaging procedures
excretory urography
Retrograde cystourethrography
Cholangiography
angiogram
splenoportography
selective coronary arteriography
discography
computerized tomography
Arteriography
peripheral arteriography
Effectiveness
How Diatrizoate Meglumine Affects PatientsDiatrizoate is a medicine used to help doctors diagnose medical problems. It contains iodine, which blocks the x-ray radiation. Depending on how it is given, it will build up in certain areas of the body, allowing the x-ray to produce a picture of the area. The areas with the medicine will appear white on the x-ray, which will help the doctor see any conditions that may exist.
How Diatrizoate Meglumine works in the bodyDiatrizoate is an X-ray contrast agent that contains iodine. It is used to create a clearer image when taking X-rays. It works because iodine is very dense and can stop X-rays. The more iodine in the solution, the better the X-ray image will be. Diatrizoate is a clear, colorless water solution, and it is safe for the body. It can be used almost anywhere in the body, including intravenously, in the spine, and in any body cavity.
When to interrupt dosage
The proposed dose of Diatrizoate Meglumine is reliant upon the identified condition, including Arteriography, angiogram and Gastrointestinal and abdominal imaging processes. The measure of dosage can be found in the following table, contingent upon the procedure of administration.Condition
Dosage
Administration
hysterosalpingogram
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
Arteriography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
splenoportography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
Cholangiography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
angiogram
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
peripheral arteriography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
excretory urography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
computerized tomography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
Gastrointestinal and abdominal imaging procedures
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
Retrograde cystourethrography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
Arteriography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
discography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
selective coronary arteriography
, 300.0 mg/mL, 180.0 mg/mL, 527.0 mg/mL, 50.0 %, 100.0 %, 30.0 %, 60.0 %, 18.0 %, 52.7 %, 66.0 %, 52.0 %, 660.0 mg/mL, 600.0 mg/mL, 760.0 mg/mL, 700.0 mg/mL, 76.0 %, 520.0 mg/mL, 0.6 mg/mg, 500.0 mg/mL, 0.9974 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Oral; Rectal, Intrauterine, Injection, solution - Intrauterine, Intravesical, Injection, solution - Intravesical, Oral, Solution, Solution - Oral, Liquid - Intravenous, Powder, Powder - Oral, Liquid - Oral, Liquid - Oral; Rectal, Powder - Oral; Rectal, Intra-arterial; Intravenous, Liquid - Intra-arterial; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Solution - Intra-arterial; Intravenous, Liquid - Intrauterine, Solution - Oral; Rectal, Powder, for solution, Powder, for solution - Oral, Intravascular, Injection, solution - Intravascular
Warnings
Diatrizoate Meglumine has eight contraindications and should not be taken while facing conditions in the table below.Diatrizoate Meglumine ContraindicationsCondition
Risk Level
Notes
Carotid Arteries
Do Not Combine
Anuria
Do Not Combine
dehydrated azotemic patients
Do Not Combine
use for sinuses communicated to subarachnoid
Do Not Combine
direct injection into spinal arteries
Do Not Combine
Myelography
Do Not Combine
Structure of vertebral artery
Do Not Combine
use for examination of dorsal cysts
Do Not Combine
Common Diatrizoate Meglumine Drug Interactions
Drug Name
Risk Level
Description
Abacavir
Minor
Diatrizoate may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Diatrizoate may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Aclidinium
Minor
Diatrizoate may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Diatrizoate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Diatrizoate may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Diatrizoate Meglumine Toxicity & Overdose RiskOverdosing on diatrizoate can be damaging to kidney cells, causing cell death, energy failure, calcium imbalance, and altering the shape of the cells. It is believed that these effects are caused by an increase in oxidative stress.
Diatrizoate Meglumine Novel Uses: Which Conditions Have a Clinical Trial Featuring Diatrizoate Meglumine?
Investigations are ongoing to assess the potential of Diatrizoate Meglumine for use in hysterosalpingogram, Arteriography and excretory urography.Condition
Clinical Trials
Trial Phases
hysterosalpingogram
0 Actively Recruiting
Cholangiography
0 Actively Recruiting
Retrograde cystourethrography
0 Actively Recruiting
peripheral arteriography
0 Actively Recruiting
selective coronary arteriography
0 Actively Recruiting
splenoportography
0 Actively Recruiting
Gastrointestinal and abdominal imaging procedures
0 Actively Recruiting
Arteriography
0 Actively Recruiting
computerized tomography
1 Actively Recruiting
Not Applicable
discography
0 Actively Recruiting
angiogram
0 Actively Recruiting
excretory urography
0 Actively Recruiting
Arteriography
0 Actively Recruiting
Diatrizoate Meglumine Reviews: What are patients saying about Diatrizoate Meglumine?
2Patient Review
6/6/2014 This didn't work well for me.
Patient Q&A Section about diatrizoate meglumine
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How do you take diatrizoate?
"Use this medication 15 to 30 minutes before your test, unless your doctor has told you to do otherwise."
Answered by AI
What is diatrizoate sodium used for?
"Diatrizoate is a contrast agent that is injected and used in radiology. It is commonly used as an x-ray contrast medium and can be used for gastrointestinal studies, angiography, and urography."
Answered by AI
What is diatrizoate meglumine used for?
"Diatrizoate meglumine injection helps to improve the clarity of imaging for diagnosing issues in the urinary bladder. Diatrizoate meglumine is a radiopaque contrast agent which means it makes different parts of the body easier to see during medical procedures such as retrograde cystourethrography."
Answered by AI
What is gastrografin used for?
"Gastrografin contains iodine and is used as a contrast medium to clearly show the area your doctor wants to investigate on X-rays, which will be your gullet (oesophagus), stomach, or intestines (gastrointestinal tract)."
Answered by AI